Leadership & Pay ·
CFO Frédéric Lombard to step down Dec. 31; cash at €96.8M as of Sept. 30
IPHAInnate Pharma SA
Innate Pharma announced that Chief Financial Officer Frédéric Lombard will depart on December 31, 2026, to pursue new career opportunities, with the company initiating a search for his replacement. The filing also reported a cash position of €96.8 million as of September 30, 2026, driven by proceeds from a recent private placement and partnership payments. Pipeline updates include expected first patient dosing in the Phase 3 TELLOMAK-3 lacutamab trial in Q1 2027 and an AstraZeneca-led PACIFIC-9 Phase 3 readout expected in H1 2027. Innate Pharma S.A. is a global clinical-stage biotechnology company developing immunotherapies for cancer patients.